SB2751 • 2026

RELATING TO WORKERS' COMPENSATION.

Healthcare Labor

Active

The official status still shows this bill as active or still awaiting another formal step.

Sponsor: IHARA
Last action: 2026-03-03
Official status: The committee on JDC deferred the measure.
Effective date: Not listed

Plain English Breakdown

Using official source text because the generated explanation was unavailable or could not be confirmed against the official bill text.

RELATING TO WORKERS' COMPENSATION.

What This Bill Does

RELATING TO WORKERS' COMPENSATION.
Workers' Compensation; Benefits; Prescription Drugs; Compounded Prescription Drugs; Physician Dispensing Timeframe; Non-FDA-Approved Drugs; Identification; Statement of Medical Necessity Defines compounded prescription drugs for the purposes of the State's Workers' Compensation Law.
Limits dispensing of prescription drugs by physician to 30 days after the industrial injury and requires all prescription drugs to be obtained through the employer's pharmacy benefit manager thereafter.
Requires prescription drugs not approved by the Food and Drug Administration (FDA), such as compounds, to be identified as compounds when listed on the treatment plan and when billed, and be supported by a statement of medical necessity documenting the case of medical need for a compound drug over an FDA-approved over-the-counter or prescription drug of similar therapeutic effect.

Limits and Unknowns

This entry is temporarily using official source text because the generated explanation could not be confirmed against the official bill text during the last sync.

Amendments

These notes stay tied to the official amendment files and metadata from the legislature.

SD1

Hawaii published version SD1

Plain English: SB2751 SD1 THE SENATE S.B.

SB2751 SD1 THE SENATE S.B.
NO.
2751 THIRTY-THIRD LEGISLATURE, 2026 S.D.
1 STATE OF HAWAII A BILL FOR AN ACT RELATING TO WORKERS' COMPENSATION .

Bill History

2026-03-03 S
The committee on JDC deferred the measure.
2026-02-24 S
The committee(s) on JDC will hold a public decision making on 03-03-26 10:15AM; Conference Room 016 & Videoconference.
2026-02-12 S
Report adopted; Passed Second Reading, as amended (SD 1) and referred to JDC.
2026-02-12 S
Reported from LBT/HHS (Stand. Com. Rep. No. 2217) with recommendation of passage on Second Reading, as amended (SD 1) and referral to JDC.
2026-02-04 S
The committee(s) on HHS recommend(s) that the measure be PASSED, WITH AMENDMENTS. The votes in HHS were as follows: 5 Aye(s): Senator(s) San Buenaventura, McKelvey, Kanuha, Keohokalole, Fevella; Aye(s) with reservations: none ; 0 No(es): none; and 0 Excused: none.
2026-02-04 S
The committee(s) on LBT recommend(s) that the measure be PASSED, WITH AMENDMENTS. The votes in LBT were as follows: 4 Aye(s): Senator(s) Elefante, Lamosao, Moriwaki, Fevella; Aye(s) with reservations: none ; 0 No(es): none; and 1 Excused: Senator(s) Ihara.
2026-01-30 S
The committee(s) on LBT/HHS has scheduled a public hearing on 02-04-26 1:00PM; Conference Room 225 & Videoconference.
2026-01-30 S
Referred to LBT/HHS, JDC.
2026-01-26 S
Passed First Reading.
2026-01-23 S
Introduced.

Official Summary Text

RELATING TO WORKERS' COMPENSATION.
Workers' Compensation; Benefits; Prescription Drugs; Compounded Prescription Drugs; Physician Dispensing Timeframe; Non-FDA-Approved Drugs; Identification; Statement of Medical Necessity
Defines compounded prescription drugs for the purposes of the State's Workers' Compensation Law. Limits dispensing of prescription drugs by physician to 30 days after the industrial injury and requires all prescription drugs to be obtained through the employer's pharmacy benefit manager thereafter. Requires prescription drugs not approved by the Food and Drug Administration (FDA), such as compounds, to be identified as compounds when listed on the treatment plan and when billed, and be supported by a statement of medical necessity documenting the case of medical need for a compound drug over an FDA-approved over-the-counter or prescription drug of similar therapeutic effect. Effective 1/1/2077. (SD1)

Current Bill Text

Read the full stored bill text

SB2751

THE SENATE

S.B. NO.

2751

THIRTY-THIRD LEGISLATURE, 2026

STATE OF HAWAII

A BILL FOR AN ACT

relating
to workers' compensation
.

BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF HAWAII:

����
SECTION
1.
�
The legislature finds that workers'
compensation costs and transparency are critical to maintaining fair and predictable
benefits for injured workers while controlling employer expenses.
�
The legislature further finds that compounded
prescription drugs can provide essential therapeutic options for injured
workers when commercially available FDA approved medications are unsuitable due
to allergies, dosage requirements, or other clinical needs.
�
However, inconsistent definitions have led to
confusion.
�
Federal law under section
503A of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 353a) establishes
clear standards for pharmacy compounding, including patient specific
prescriptions, quality requirements for bulk substances, and exclusions for
simple reconstitution.
�
Aligning state
law with these standards will promote patient safety by ensuring compounded
drugs meet recognized quality benchmarks, enhance regulatory consistency
between state and federal oversight.

����
Accordingly,
the purpose of this Act is to align state law with federal standards for
pharmacy compounding by codifying the federal definition of a "compounded
drug", thereby promoting regulatory consistency, supporting patient
safety, and ensuring access to individualized medications when an FDA approved
drug is not medically appropriate for a particular patient.
�
This Act incorporates by reference section
503A of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 353a) and
clarifying federal guidance.

����
SECTION
2
.
�
Section 386-21.7, Hawaii Revised Statutes, is
amended by amending subsection (f) to read as follows:

����
"(f)
�
For purposes of this section[
,
"equivalent
]
:

����
"Compounded
prescription drug" means a drug product that is compounded by a licensed
pharmacist in a state licensed pharmacy, or a licensed physician, for an
identified individual patient based on the receipt of a valid prescription
order or a notation, approved by the prescribing practitioner, on the
prescription order that a compounded product is necessary for the identified
patient, and otherwise meets the requirements of
�
title 21 United States Code section 353.

����
"Equivalent

generic drug product" has the same meaning as provided in section 328-91."

����
SECTION 3.
�
This Act does not affect rights and duties
that matured, penalties that were incurred, and proceedings that were begun
before its effective date.

����
SECTION
4.
�
Statutory material to be repealed is
bracketed and stricken.
�
New statutory
material is underscored.

����
SECTION 5.
�
This Act shall take effect on July 1, 2026.

INTRODUCED BY:

_____________________________

Report Title:

Workers'
Compensation; Benefits; Compounded Prescription Drugs

Description:

Defines
compounded prescription drugs for the purposes of workers' compensation law.

The summary description
of legislation appearing on this page is for informational purposes only and is
not legislation or evidence of legislative intent.